<code id='AEA42235AF'></code><style id='AEA42235AF'></style>
    • <acronym id='AEA42235AF'></acronym>
      <center id='AEA42235AF'><center id='AEA42235AF'><tfoot id='AEA42235AF'></tfoot></center><abbr id='AEA42235AF'><dir id='AEA42235AF'><tfoot id='AEA42235AF'></tfoot><noframes id='AEA42235AF'>

    • <optgroup id='AEA42235AF'><strike id='AEA42235AF'><sup id='AEA42235AF'></sup></strike><code id='AEA42235AF'></code></optgroup>
        1. <b id='AEA42235AF'><label id='AEA42235AF'><select id='AEA42235AF'><dt id='AEA42235AF'><span id='AEA42235AF'></span></dt></select></label></b><u id='AEA42235AF'></u>
          <i id='AEA42235AF'><strike id='AEA42235AF'><tt id='AEA42235AF'><pre id='AEA42235AF'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:fashion    Page View:338
          Adobe

          Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to expect smaller and fewer checks as well as possible market consolidation but not to abandon hope just yet as investments stabilize following a sharp drop-off.

          As customers — often health systems, payers, or employers — and backers plot how they’ll invest shrinking budgets, they’re increasingly savvy about metrics, investors told STAT. They’re also less interested in rapid growth, and more keen on startups that can demonstrate savings and efficiency.

          advertisement

          That’s a sharp contrast from the unrestrained health tech investments that peaked in 2021, fueled by a pandemic-era frenzy for virtual appointments, mental health care and app-based therapies.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          A Q&A with the global head of Boehringer Ingelheim's innovation unit
          A Q&A with the global head of Boehringer Ingelheim's innovation unit

          MichelPairetCourtesyBoehringerIngelheimLONDON—Ataneventherelastweek,theGermanpharmaceuticalfirmBoehr

          read more
          Anesthesiologist group: stop taking Ozempic before surgery
          Anesthesiologist group: stop taking Ozempic before surgery

          EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

          read more

          In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

          CourtesyBristolMyersSquibbBristolMyersSquibbsaidthatitwouldpurchaseMiratiTherapeutics,makerofthecanc